Active surveillance is the preferred approach to clinical stage I testicular cancer. - Wikidata - wikimedia - TriplyDB

Active surveillance is the preferred approach to clinical stage I testicular cancer.

Active surveillance is the preferred approach to clinical stage I testicular cancer.

http://www.wikidata.org/entity/Q44237218

about

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.Reimbursements and frequency of tests in privately insured testicular cancer patients in the United States: Implications to national guidelines.Testicular cancer: Optimal management of stage I seminoma in 2015.Active surveillance in prostate cancer: a concept analysis.A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion Controversies in the management of clinical stage I testicular seminoma.Management of clinical stage I nonseminomatous germ cell tumors.Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.Management of stage I testicular germ cell tumours.Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database.Best treatment option for clinical stage I seminoma patients.Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy.The Sound of Silence: A Proxy for Platinum Toxicity.Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors.Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.Adolescent and Young Adult Testicular Germ Cell Tumors: Special Considerations.Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I.Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

P2860

Q26797518-18177140-1A56-46B2-A569-5FD25B1FAED4 Q26865862-7EC7EA53-D981-42FF-B014-D283AD7E324F Q31108321-10BC849D-5688-45BC-8E91-2C345A127A88 Q33605033-BD931FEF-73F3-4800-B10B-AFEBD1C7EC3A Q34472724-48CFBD3A-932C-4FD1-A9DA-EAAB8B2FF2BB Q35898357-9661F16B-63A6-4F42-88D3-A31407CF18D6 Q36007972-9D96B54A-57EB-4030-89E2-2AA3B2B6078C Q36840698-6020339B-DF37-4FC5-A3B9-A2F76D07A13D Q38220484-8328D301-3739-4590-9286-097BCE5B9F2A Q38656908-BBBAF491-B01D-4C2A-BF5F-03CE72DE05A2 Q38952121-EA19FC44-04FB-4413-BE94-62A92A998479 Q39391858-0A31EC4E-3B82-4BFA-BFB4-96E55DDE8E42 Q40678226-53F74716-673E-40D9-8251-8239457F5F4F Q41732986-38DB454A-FB4C-4049-BB19-704816834FB1 Q42395952-7BFFA110-6E23-48E5-B578-C7658A7C7CB8 Q47813874-E908ACAD-DF5F-4EA0-8B8C-5ED87B7B5764 Q50062284-9AF536C7-2DEB-4671-AC47-3E6ACFE57671 Q50604982-9A04051D-CC49-4A6B-9BA8-55BE65A28046 Q51745955-669EF872-B08D-4BCD-9DAD-31FE436F325E Q52718921-F65F1E98-C9C3-4A61-B748-4C1D5F2D7586 Q55209489-B66EDF21-5B9F-44FC-A50F-D964867CEBB8 Q55317807-19EC109C-7D94-425C-A0AD-0AAE008F8A8A

P2860

Active surveillance is the preferred approach to clinical stage I testicular cancer.

http://www.wikidata.org/entity/Q44237218

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Active surveillance is the preferred approach to clinical stage I testicular cancer.

@en

Active surveillance is the preferred approach to clinical stage I testicular cancer.

@nl

type

label

Active surveillance is the preferred approach to clinical stage I testicular cancer.

@en

Active surveillance is the preferred approach to clinical stage I testicular cancer.

@nl

prefLabel

Active surveillance is the preferred approach to clinical stage I testicular cancer.

@en

Active surveillance is the preferred approach to clinical stage I testicular cancer.

@nl

P1433

Q44237218-3D78C1BE-6AC3-4C4E-82CA-BEC390C8AD05

P1476

Q44237218-993BF857-1D70-4F91-8012-427A583B4F33

P2093

Q44237218-20642E0A-05CC-436E-9FEC-C19C0D66C145

Q44237218-5774D1C4-725D-4E95-A680-9744CE42A46B

Q44237218-5B83A424-98A8-42D7-AB7E-853933C593E7

Q44237218-6ADB235C-0163-4D07-9B0B-7B25EC005A6C

Q44237218-6D2F2294-A44C-490E-B00D-9E5D64B29770

Q44237218-71D5845E-7804-48F7-A339-89EA9560D9E0

Q44237218-74A690BE-3A75-4CA8-A30B-3F38D6C89D48

Q44237218-7870C318-E990-44C9-A2AF-3433F1A0DB9B

Q44237218-7D42018B-1E88-4FA9-9DF0-29BF4A35CA4F

Q44237218-83D23ED1-27D1-4F6F-860C-DA1FD75889CC

P304

Q44237218-53C9D8E9-83D4-46B1-B895-CFD0E9FABEFE

P31

Q44237218-2B6B3B7D-8C4D-49D9-9E2F-8E08888EF795

P356

Q44237218-465E0A80-42B6-4DCA-A4F5-964CEABFF856

P407

Q44237218-4F899963-B9C5-49DE-81F3-63D6889FFF32

P433

Q44237218-F58A26FB-BBBE-4115-B587-4F1286A993E2

P478

Q44237218-6874F685-715E-49A6-9351-B387FABE6700

P50

Q44237218-67EE213C-55AC-48BE-B11F-3195209E2A49

Q44237218-A874CEF1-2404-405B-BAE6-56E715F701D6

Q44237218-E4E29E01-68C7-4802-89D3-597898191CFF

P577

Q44237218-4723D072-D0A0-41BC-A9F0-7145BC941DC9

P5875

Q44237218-D6B6C56C-8F15-49B9-B047-BCAB5D62B01D

P698

Q44237218-4FBBF3A4-F496-4A00-A194-3385224284DA

P356

JCO.2012.47.6010

P1433

Journal of Clinical Oncology

P1476

Active surveillance is the preferred approach to clinical stage I testicular cancer.

@en

P2093

Alan So

http://www.w3.org/2001/XMLSchema#string

Brandon Hayes-Lattin

http://www.w3.org/2001/XMLSchema#string

Bruce Roth

http://www.w3.org/2001/XMLSchema#string

Carsten Bokemeyer

http://www.w3.org/2001/XMLSchema#string

Christian Kollmannsberger

http://www.w3.org/2001/XMLSchema#string

Christopher J Sweeney

http://www.w3.org/2001/XMLSchema#string

Christopher Porter

http://www.w3.org/2001/XMLSchema#string

Clair Beard

http://www.w3.org/2001/XMLSchema#string

Craig R Nichols

http://www.w3.org/2001/XMLSchema#string

Karim Fizazi

http://www.w3.org/2001/XMLSchema#string

P304

3490-3493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.47.6010

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Siamak Daneshmand

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256425448

http://www.w3.org/2001/XMLSchema#string

P698

24002502

http://www.w3.org/2001/XMLSchema#string